Abstract
The value of adrenaline for reducing mortality in experimental cardiac arrest was first demonstrated by Crile and Dolley in 1906 [l]. Catecholamines such as adrenaline achieve their pharmacological effects by acting at two distinct adrenoceptors, known as (Y and /3 [2]. While some agonists are relatively specific for one receptor subtype, adrenaline is a mixed agonist acting at both adrenoceptors. This review will consider the evidence supporting the use of adrenaline as an aid to cardiopulmonary resuscitation. The mechanism of action and dose-response relationships for adrenaline will be considered. Experimental results from comparisons between adrenaline and adrenoceptor agonists with greater receptor specificity will be reviewed. After discussing the evidence and the limitations of these data, recommendations for current clinical practice will be made.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call